It really feels like the sector wants to continue the trend higher but the broader market is not going to let it. I think if the broader market sentiment were neutral, then the sector would be moving higher. I do not think the sector has a chance to move higher in the midst of a […]
With all the drama in the markets this week, I have to say that looking at the sector there does not seem to be a ton of damage done to the chart. It looks like we have create a little downtrend in September but a breakout of that mini-downtrend could trigger a run to higher […]
Not a good start to the week for the markets and it seems related to the Evergrande, which is China’s second largest real estate company that looks on the verge of going bankrupt. The story is pretty typical with a property developer using too much leverage to grow too fast and get involve in unnecessary […]
The sector sort of had that reversal yesterday but it honestly did not seem particularly strong. We are red this morning so perhaps we can get a stronger reversal today to really put in that higher low but the sector seems a little weak. I would have thought we would have at least gotten a […]
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.